Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only change noted is an increase in the notional share interests of Mr. A P Witty.
Management Commentary and Risks
The filing details a transaction under the dividend re-investment element of the Deferred Annual Bonus Plan. On April 11, 2011, Mr. A P Witty acquired 395 Ordinary shares via personal contribution and 395 Ordinary shares via company matching contribution at a price of £12.13 per share. This followed dividends paid to shareholders on April 7, 2011. The notional dividends accrued will be paid out based on the vesting percentage of the participant's deferred annual bonus holdings after the relevant three-year measurement period. No other risks, contingencies, or unusual items are disclosed.
Investor Verification Points
- Verify the vesting schedule and conditions for the 2009 Deferred Annual Bonus Plan.
- Confirm the total notional share holdings of Mr. A P Witty following this transaction.
- Review the company's broader financial results for the period ending April 2011 in separate reports, as they are not included here.